Kerry Wentworth, Chief Regulatory Officer at Flexion Therapeutics Inc (FLXN), sold 622 shares at $12.36 ($8K) on 2019-01-03, disclosed to the SEC on 2019-01-04.
Scheduled sale ($8k) by Chief Regulatory Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| Filing → |
| NUVB | SELL | 2026-04-08 | $904K | — | Filing → |
| NUVB | BUY | 2025-06-18 | $90K | — | Filing → |
| FLXN | SELL | 2021-07-20 | $25K | — | Filing → |